Astec Lifesciences' Q1 FY 2025-26 Quarterly Results

Result Summary

• Astec Lifesciences Ltd reported a 41.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 30.3%.
• Its expenses for the quarter were down by 20.5% QoQ and 5.6% YoY.
• The net profit increased 3340.6% QoQ and decreased 16.8% YoY.
• The earnings per share (EPS) of Astec Lifesciences Ltd declined at 16.9 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Astec Lifesciences Ltd is a company that operates primarily in the agrochemical industry, specializing in the production of active ingredients, intermediates, and formulations used in the agriculture sector. The company focuses on manufacturing high-quality products that enhance crop protection and yield. Astec Lifesciences is known for its expertise in complex chemistries and its commitment to sustainable agricultural practices. The company has been expanding its global presence, aiming to cater to the increasing demand for agrochemical products. As of the last update in October 2023, no specific recent major developments have been highlighted.

Revenue

For the quarter Q1FY26, Astec Lifesciences Ltd reported a total income of ₹91.59 crores. This represents a decrease of 41.2% compared to the previous quarter (Q4FY25), where the company recorded a total income of ₹155.80 crores. However, when comparing the year-over-year performance, the total income increased by 30.3% from ₹70.30 crores in Q1FY25. These figures indicate a significant fluctuation in quarterly revenues, with a notable improvement when assessed on an annual basis.

Profitability

Astec Lifesciences Ltd reported a Profit Before Tax (PBT) of -₹33.02 crores for Q1FY26, showing a substantial decrease from the PBT of -₹0.93 crores in Q4FY25. However, compared to Q1FY25, where the PBT was -₹61.64 crores, there is an improvement. The Profit After Tax (PAT) for Q1FY26 was -₹33.03 crores, which also reflects a considerable decline from -₹0.96 crores in the previous quarter. When compared year-over-year, the PAT improved from -₹39.71 crores in Q1FY25. The Earnings Per Share (EPS) for Q1FY26 stood at -₹16.90, which decreased from -₹0.50 in the preceding quarter, but showed an improvement against -₹20.30 in Q1FY25.

Operating Metrics

The total expenses for Astec Lifesciences Ltd in Q1FY26 were reported at ₹124.60 crores, marking a decrease of 20.5% from Q4FY25, which had expenses of ₹156.72 crores. Year-over-year, the expenses decreased by 5.6% from ₹131.93 crores in Q1FY25. The tax expense for Q1FY26 was minimal at ₹0.01 crores, which decreased from ₹0.04 crores in Q4FY25, and significantly reduced from a tax credit of -₹21.92 crores in Q1FY25. These figures highlight the company's cost management and tax strategies over the quarters.